Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma Clinical Trial
Official title:
An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).
The drug being tested in this study is called MLN1117. MLN1117 is being tested to treat
people who have locally advanced or metastatic gastric or gastroesophageal junction
adenocarcinoma. This study will look at the dose-limiting toxicity and response to treatment
in participants who take MLN1117 in combination with TAK-659, alisertib, paclitaxel, or
docetaxel.
The study will enroll 32 participants in the dose escalation phase (Part 1) and 118
participants in the dose expansion phase (Part 2). Participants will be assigned to 1 of the
7 treatment groups:
- MLN1117 300 mg+Alisertib
- MLN1117 600 mg+Alisertib
- MLN1117 300 mg+Paclitaxel
- MLN1117 600 mg+Paclitaxel
- MLN1117 300 mg+TAK-659
- MLN1117 200 mg+Docetaxel
- MLN1117 300 mg+Docetaxel
In Part 1, the dose of MLN1117 will be increased step by step. All participants will be asked
to take tablets of MLN1117 for 3 days on and 4 days off per week in 28-day treatment cycles
or 21-day treatment cycles when given in combination with the other companion drugs.
This multi-center trial will be conducted in Spain and United States. The overall time to
participate in this study is 10 months for Part 1 and 24 months for Part 2. Participants will
make multiple visits to the clinic, and be contacted by telephone, e-mail or mail every 12
weeks for up to 6 months or 1 year after the last dose of study drug for a follow-up
assessment.
;